Unlike traditional pharmaceuticals, cell therapies are patient-specific (one batch, one patient). This makes the centralized global manufacturing model inefficient. A decentralized, local production network is essential for global accessibility and scalability, fundamentally changing the supply chain strategy.
The CTMC model, by being physically and collaboratively embedded within MD Anderson Cancer Center, creates a tight feedback loop. This "patient-adjacent" approach accelerates IND filings, regulatory interactions, and clinical study activation by streamlining logistics, communication, and regulatory processes.
To expand cell therapy globally, building facilities is insufficient. The key is forming alliances that transfer manufacturing processes, analytics knowledge, and provide local regulatory support to enable regions like Brazil to adopt these complex treatments and build self-sufficient ecosystems.
A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.
While in vivo CAR-T could eliminate complex manufacturing, it lacks the safety guardrails of ex vivo methods. Clinicians cannot monitor the effective dose, count viral integrations, or guarantee that only T cells are engineered, posing significant risks of uncontrolled off-target effects.
To increase safety and efficacy, next-generation CAR-T therapies use "logic-gated" designs. These constructs only activate when they detect the co-expression of multiple antigens—a signature unique to tumor cells—thereby avoiding off-target toxicity on healthy tissues that may express only one of the antigens.